Chloroquine
- Generic Name
- Chloroquine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3
- CAS Number
- 54-05-7
- Unique Ingredient Identifier
- 886U3H6UFF
- Background
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Chloroquine was granted FDA Approval on 31 October 1949.
- Indication
Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
Chloroquine is also used off label for the treatment of rheumatic diseases, as well as treatment and prophylaxis of Zika virus. Chloroquine is currently undergoing clinical trials for the treatment of COVID-19.
- Associated Conditions
- Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
- Associated Therapies
- -
Ethiopia Antimalarial in Vivo Efficacy Study 2012
- Conditions
- Plasmodium Vivax Infection
- Interventions
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 398
- Registration Number
- NCT01680406
- Locations
- 🇪🇹
Bishoftu Malaria Center, Debre Zeit, Ethiopia
🇪🇹Batu Health Center, Zeway, Ethiopia
Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand
- Conditions
- Acute Uncomplicated Malaria With P.Vivax Infection
- Interventions
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 120
- Registration Number
- NCT01662700
- Locations
- 🇹🇭
Kraburi Hospital, Ranong, Thailand
🇹🇭Khunhan Hospital, Srisaket, Thailand
🇹🇭Kap Choeng Hospital, Surin, Thailand
Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)
- Conditions
- Vivax Malaria
- Interventions
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 680
- Registration Number
- NCT01640574
- Locations
- 🇹🇭
Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand
Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Maastricht Radiation Oncology
- Target Recruit Count
- 5
- Registration Number
- NCT01575782
- Locations
- 🇳🇱
MAASTRO clinic, Maastricht, Limburg, Netherlands
Chloroquine Population Pharmacokinetics in Pre and Post-partum Women
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 49
- Registration Number
- NCT01546961
- Locations
- 🇹🇭
Shoklo Malaria Research Unit, Tak, Mae Sot, Thailand
Sanaria™ PfSPZ Challenge Vaccine
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2013-09-13
- Target Recruit Count
- 30
- Registration Number
- NCT01546389
- Locations
- 🇺🇸
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States
Malaria Challenge in Healthy Volunteers
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2012-12-13
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT01500980
- Locations
- 🇺🇸
Seattle Biomedical Research Institute's Malaria Clinical Trials Center, Seattle, Washington, United States
Chloroquine for Malaria in Pregnancy
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2016-12-28
- Target Recruit Count
- 900
- Registration Number
- NCT01443130
- Locations
- 🇲🇼
Blantyre Malaria Project - Queen Elizabeth Central Hospital, Blantryre, Blantyre, Malawi
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 11
- Registration Number
- NCT01438177
- Locations
- 🇺🇸
NYU Cancer Institute, New York, New York, United States
Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria
- First Posted Date
- 2011-06-22
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 380
- Registration Number
- NCT01378286
- Locations
- 🇧🇷
Administrative office, Sao Paulo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.